BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38031784)

  • 1. Current Perspectives of Immunotherapy for Hepatocellular Carcinoma.
    Liu X; Lei X; Huang S; Yang X
    Comb Chem High Throughput Screen; 2023 Nov; ():. PubMed ID: 38031784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Research progress of immunotherapy alone and in combination for liver cancer].
    Wu ZJL; Li K; Zhang K; Gong WD
    Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):471-474. PubMed ID: 32660173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
    Liu X; Qin S
    Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bibliometric study of immunotherapy for hepatocellular carcinoma.
    Li Z; Zhang Y; Zhang B; Guo R; He M; Liu ZL; Yang L; Wang H
    Front Immunol; 2023; 14():1210802. PubMed ID: 37600802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.
    Pourhamzeh M; Asadian S; Mirzaei H; Minaei A; Shahriari E; Shpichka A; Es HA; Timashev P; Hassan M; Vosough M
    Mol Cell Biochem; 2023 Jan; 478(1):23-37. PubMed ID: 35708866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease.
    Cassese G; Han HS; Lee B; Lee HW; Cho JY; Panaro F; Troisi RI
    World J Hepatol; 2022 Oct; 14(10):1862-1874. PubMed ID: 36340753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progress in immunotherapy for hepatocellular carcinoma].
    Shen Z; Li M; Bai S; Yang Q; Zhang F; Tang M; Guo J; Yang Z
    Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2326-2338. PubMed ID: 31880139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
    Li Q; Han J; Yang Y; Chen Y
    Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
    Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
    Front Immunol; 2021; 12():765101. PubMed ID: 34675942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives.
    Mandlik DS; Mandlik SK; Choudhary HB
    World J Gastroenterol; 2023 Feb; 29(6):1054-1075. PubMed ID: 36844141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
    Guizhen Z; Guanchang J; Liwen L; Huifen W; Zhigang R; Ranran S; Zujiang Y
    Front Endocrinol (Lausanne); 2022; 13():918869. PubMed ID: 36093115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiality of immunotherapy against hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Sep; 21(36):10314-26. PubMed ID: 26420958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for hepatocellular carcinoma.
    Zhou M; Liu B; Shen J
    Clin Exp Med; 2023 Jul; 23(3):569-577. PubMed ID: 36001163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.
    Reiter FP; Ben Khaled N; Ye L; Zhang C; Seidensticker M; Op den Winkel M; Denk G; Geier A; De Toni EN
    Dig Dis; 2022; 40(5):565-580. PubMed ID: 34644705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma.
    Shen C; Li M; Duan Y; Jiang X; Hou X; Xue F; Zhang Y; Luo Y
    Front Immunol; 2023; 14():1170207. PubMed ID: 37304265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
    Caraballo Galva LD; Cai L; Shao Y; He Y
    J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression.
    Kotsari M; Dimopoulou V; Koskinas J; Armakolas A
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
    Zhu Y; Qin LX
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):420-429. PubMed ID: 35977874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.